Finder makes money from featured partners, but editorial opinions are our own.

How to buy Johnson And Johnson (JNJ) shares in Australia

Learn how to easily invest in Johnson And Johnson shares.

Johnson & Johnson is a drug manufacturers - general business with stocks listed in the US. Johnson And Johnson shares (JNJ) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was US$158.55 – an increase of 4.23% over the previous week. Here's how to invest if you're based in Australia.

How to buy shares in Johnson And Johnson

  1. Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Johnson And Johnson. Find the share by name or ticker symbol: JNJ. Research its history to confirm it's a solid investment that matches your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Johnson And Johnson reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$158.55, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Johnson And Johnson, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Johnson And Johnson. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.

Johnson And Johnson stock price (NYSE:JNJ)

Use our graph to track the performance of JNJ stocks over time.

Have Johnson And Johnson's shares ever split?

Johnson And Johnson's shares were split on a 2:1 basis on 13 June 2001. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your Johnson And Johnson shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Johnson And Johnson shares which in turn could have impacted Johnson And Johnson's share price.

Johnson And Johnson shares at a glance

Information last updated 2023-12-05.
52-week rangeUS$143.7985 - US$175.7081
50-day moving average US$152.9336
200-day moving average US$159.3905
Target priceUS$175.1
PE ratio 29.8647
Dividend yield US$4.64 (3%)
Earnings per share (TTM) US$5.32

Johnson And Johnson share growth calculator

US$

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

Johnson And Johnson price performance over time

Historical closes compared with the last close of $158.55

1 week (2023-11-30) 2.52%
1 month (2023-11-07) 5.07%
3 months (2023-09-07) -0.92%
6 months (2023-06-07) 0.02%
1 year (2022-12-07) -10.51%
2 years (2021-12-07) -2.94%
3 years (2020-12-07) 6.43%
5 years (2018-12-07) 9.02%

Compare trading platforms to buy Johnson And Johnson shares

1 - 6 of 6
Name Product Standard brokerage for US shares Currency conversion fee Asset class
eToro
Finder AwardExclusive
eToro
US$0
50-150 pips
ASX shares, Global shares, US shares, ETFs
CFD service. Capital at risk.
Finder exclusive: Get 12 months of investment tracking app Delta PRO for free when you fund your eToro account (T&Cs apply).
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
Finder Award
IG Share Trading
US$0
0.70%
ASX shares, Global shares, US shares, UK shares, ETFs
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian and international shares, plus get access to 24-hour customer support.
Moomoo Share Trading
US$0.99
55 pips or 0.0055 AUD/USD
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get an additional 30 days on top of the regular brokerage-free period for new accounts (see link for details). T&Cs apply. Please note that additional pass-through fees and foreign exchange conversion spreads may also apply.
Trade shares on the ASX, the US markets and buy ETFs with Moomoo. Plus join a community over 20 million investors.
CMC Invest
Finder Award
CMC Invest
US$0
0.60%
ASX shares, Global shares, Options trading, US shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 35,000 products, including shares, crypto, ETFs and managed funds, with access to 15 major global and Australian stock exchanges. Plus, buy Aussie shares for $0 brokerage up to $1,000. (Limited to one buy order per stock per trading day).
Webull
US$0.25
0.50% (50 pips)
ASX shares, Options trading, US shares, ETFs
Earn US$100 in cash vouchers when you fund your new account and maintain a minimum balance of US$2,000 by Dec 29 until March 31, 2024. Plus, earn up to 5.3% p.a. interest on your US cash account (T&Cs apply).
Trade ASX and US stocks and US options, plus gain access to inbuilt news platforms and educational resources. You can also start trading for less with fractional shares.
Tiger Brokers
Exclusive
Tiger Brokers
US$2
37 pips
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get 10 brokerage-free trades for the US or ASX market for the first 180 days and US$50 fractional shares when you deposit at least US$500. Plus, all new customers get 1 free trade per month for the first 12 months (T&Cs apply).
Get one brokerage-free trade per month for the first 12 months for US or ASX markets. T&Cs apply.
loading
The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Johnson And Johnson stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is Johnson And Johnson under- or over-valued?

Valuing Johnson And Johnson stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Johnson And Johnson's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Johnson And Johnson's P/E ratio

Johnson And Johnson's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 30x. In other words, Johnson And Johnson shares trade at around 30x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Johnson And Johnson's PEG ratio

Johnson And Johnson's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.5718. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Johnson And Johnson's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Johnson And Johnson's EBITDA

Johnson And Johnson's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$35 billion (£27.9 billion).

The EBITDA is a measure of a Johnson And Johnson's overall financial performance and is widely used to measure stock profitability.

Johnson And Johnson share price volatility

Over the last 12 months, Johnson And Johnson's shares have ranged in value from as little as US$143.7985 up to US$175.7081. A popular way to gauge a stock's volatility is its "beta".

JNJ.US volatility(beta: 0.57)Avg. volatility(beta: 1.00)LowHigh

Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Johnson And Johnson's is 0.573. This would suggest that Johnson And Johnson's shares are less volatile than average (for this exchange).

Johnson And Johnson financials

Revenue TTM US$98.7 billion
Operating margin TTM 30.07%
Gross profit TTM US$64 billion
Return on assets TTM 10.11%
Return on equity TTM 19.19%
Profit margin 35.1%
Book value 29.59
Market capitalisation US$382.5 billion

TTM: trailing 12 months

Johnson And Johnson share dividends

45%

Dividend payout ratio: 44.8% of net profits

Recently Johnson And Johnson has paid out, on average, around 44.8% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Johnson And Johnson shareholders could enjoy a 3% return on their shares, in the form of dividend payments. In Johnson And Johnson's case, that would currently equate to about $4.64 per share.

While Johnson And Johnson's payout ratio might seem fairly standard, it's worth remembering that Johnson And Johnson may be investing much of the rest of its net profits in future growth.

Johnson And Johnson's most recent dividend payout was on 5 December 2023. The latest dividend was paid out to all shareholders who bought their shares by 20 November 2023 (the "ex-dividend date").

Johnson And Johnson's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Johnson And Johnson.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Johnson And Johnson's total ESG risk score

Total ESG risk: 35.8

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Johnson And Johnson's overall score of 35.8 (as at 01/01/2019) is pretty weak – landing it in it in the 72nd percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Johnson And Johnson is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Johnson And Johnson's environmental score

Environmental score: 3.79/100

Johnson And Johnson's environmental score of 3.79 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson And Johnson is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Johnson And Johnson's social score

Social score: 25.14/100

Johnson And Johnson's social score of 25.14 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson And Johnson is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Johnson And Johnson's governance score

Governance score: 14.87/100

Johnson And Johnson's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that Johnson And Johnson is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Johnson And Johnson's controversy score

Controversy score: 4/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Johnson And Johnson scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Johnson And Johnson has a damaged public profile.

Environmental, social, and governance (ESG) summary

Johnson & Johnson was last rated for ESG on: 2019-01-01.

Total ESG score 35.8
Total ESG percentile 72.38
Environmental score 3.79
Environmental score percentile 7
Social score 25.14
Social score percentile 7
Governance score 14.87
Governance score percentile 7
Level of controversy 4

Johnson And Johnson overview

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment offers electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and contact lenses and ophthalmic technologies related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and 6. Finder Group Privacy & Cookies Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site